PURPOSE: This study sought to determine the relationship between furosemide dose and hospital length of stay in acute decompensated heart failure (ADHF) patients at a teaching institution.
METHODS: A retrospective chart review was conducted for the period from January 1, 2007 to December 31, 2007. Two electronic databases were utilized to identify patients admitted for ADHF who received IV or PO furosemide during their hospitalization. 122 records were included. The primary endpoint was the correlation between the patient’s daily furosemide dose and length of stay. Secondary endpoints included the difference in length of stay between patients that received low, medium and high furosemide doses and the relationship between baseline serum creatinine and length of stay. Descriptive statistics, ANOVA, and Pearson’s Correlation (r) were utilized in the data analysis.
RESULTS: No correlation was found between patient’s total daily dose of furosemide and length of stay (r = -0.102). There was no difference in length of stay between patients who received low, medium and high doses of furosemide (F = 1.368, p = 0.259). Lastly, there was no significant difference in lengths of stay between patients with a serum creatinine ≤ 1.5 and those with a serum creatinine > 1.6.
CONCLUSION: Our study suggests that inpatient furosemide doses do not affect duration of hospitalization.
CLINICAL IMPLICATIONS: Loop diuretics are a well-established treatment modality for ADHF, however, there are some important limitations associated with the utility and tolerability of diuretic use. Furthermore, several small studies have found negative outcomes with the use of high dose diuretics. Although, our study did not reveal any correlations between the dose of furosemide and patient’s length of stay there are multiple inherent limitations associated with a retrospective analysis design. Due to the limited amount of data available, a large-scale randomized controlled trial of diuretic therapy in acute heart failure patients with long-term follow up to assess morbidity and mortality is warranted.
DISCLOSURE: Jun Chiong, No Financial Disclosure Information; No Product/Research Disclosure Information